Oculis Holding AGOCS
13F holders, Q2 2024 (June 30)11holders +2
2new positions
0sold out
$11.95avg. 13F price*
At the end of Q2 2024, 11 institutions reported holding Oculis Holding AG (OCS) in their 13F filings, up 2 from Q1 2024. 2 opened new positions and 0 sold out. The largest holders were Pivotal bioVenture Partners Investment Advisor LLC ($19.1M), Aberdeen Group plc ($13.2M) and Nan Fung Group Holdings Ltd ($5.2M).
- Company
- Oculis Holding AG
- CUSIP
- H5870P102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $602K |
| Exits | 0 | $0 |
All 13F filers, Q1 2024 → Q2 2024: 65,773 shares bought and 130,349 shares sold, net −64,576 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Pivotal bioVenture Partners Investment Advisor LLC | 14.66% | No change | 1,595,918 | $19.1M |
| Aberdeen Group plc | 0.03% | Reduce -10.4% | 1,100,432 | $13.2M |
| Nan Fung Group Holdings Ltd | 5.56% | No change | 436,378 | $5.2M |
| Compagnie Lombard Odier SCmA | 0.02% | No change | 95,750 | $1.1M |
| ExodusPoint Capital Management, LP | 0.01% | New | 50,366 | $602K |
| Bank of America Corp. | 0.00% | Reduce -13.8% | 17,155 | $205K |
| UBS Group AG | 0.00% | Add +1404.1% | 16,500 | $197K |
| Geode Capital Management, LLC | 0.00% | No change | 14,944 | $179K |
| Dupont Capital Management Corp. | 0.00% | No change | 4 | $48 |
| JPMorgan Chase & Co. | 0.00% | No change | 1 | $12 |
| Royal Bank of Canada | 0.00% | New | 4 | $0 |
"% of holder's portfolio" is OCS's weight in each manager's 13F, not the share of Oculis Holding AG the manager owns.